Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

被引：0

作者：

Zhang, Yi ^{[1
]}

Zhou, Hu ^{[2
]}

Suo, Shanshan ^{[1
]}

Zhuang, Junling ^{[3
]}

Yang, Linhua ^{[4
]}

He, Aili ^{[5
]}

Liu, Qingchi ^{[6
]}

Du, Xin ^{[7
]}

Gao, Sujun ^{[8
]}

Li, Yarong ^{[9
]}

Li, Yan ^{[10
]}

Chen, Yuqing ^{[11
]}

Wu, Wen ^{[12
]}

Zhu, Huanling ^{[13
]}

He, Guangsheng ^{[14
]}

Hong, Mei ^{[15
]}

Jiang, Qian ^{[16
]}

Jiang, Zhongxing ^{[17
]}

Jing, Hongmei ^{[18
]}

Wang, Jishi ^{[19
]}

Xu, Na ^{[20
]}

Yue, Lingling ^{[21
]}

Zheng, Cuiping ^{[22
]}

Zhou, Zeping ^{[23
]}

Jin, Chenghao ^{[24
]}

Li, Xin ^{[25
]}

Liu, Lin ^{[26
]}

Xu, Yajing ^{[27
]}

Wu, Dengshu ^{[28
]}

Zhang, Feng ^{[29
]}

Zhang, Jin ^{[30
]}

Xiao, Zhijian ^{[31
]}

Jin, Jie ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China

[2] Henan Prov Hematol Hosp, Dept Hematol, Zhengzhou, Henan, Peoples R China

[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China

[4] Second Hosp Shanxi Med Univ, Neurosurg, Taiyuan, Peoples R China

[5] Xi An Jiao Tong Univ, Dept Neurol, Affiliated Hosp 2, Xian, Peoples R China

[6] Hebei Med Univ, Hosp 1, Shijiazhuang, Peoples R China

[7] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Hematol, Guangzhou, Peoples R China

[8] First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China

[9] Second Hosp Jilin Univ, Dept Hematol & Oncol, Changchun, Peoples R China

[10] China Med Univ, Affiliated Hosp 1, Dept Hematopathol, Shenyang, Peoples R China

[11] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China

[12] Shanghai Jiao Tong Univ, Shanghai Inst Hematol, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom,Ruijin Hosp,Sch Med, Shanghai, Peoples R China

[13] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China

[14] Nanjing Med Univ, Key Lab Hematol, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalize,Affiliated, Nanjing, Peoples R China

[15] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[16] Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp, Beijing, Peoples R China

[17] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[18] Peking Univ Third Hosp, Beijing, Peoples R China

[19] GuiZhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang City, Peoples R China

[20] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

[21] Lanzhou Univ Second Hosp, Dept Hematol & Oncol, Lanzhou, Peoples R China

[22] Wenzhou Cent Hosp, Dept Oncol 2, Wenzhou, Peoples R China

[23] Kunming Med Univ, Affiliated Hosp 2, Kunming, Peoples R China

[24] Jiangxi Prov Peoples Hosp, Nanchang, Peoples R China

[25] Cent South Univ, Third Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[26] Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, Chongqing, Peoples R China

[27] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China

[28] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[29] Bengbu Med Coll, Affiliated Hosp 1, Dept Hematol, Bengbu, Peoples R China

[30] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Hematol, Hangzhou, Peoples R China

[31] Chinese Acad Med Sci & Peking Union Med Coll, MDS & MPN Ctr, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-202790

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3165 / 3166

页数：2

共 50 条

[11] The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial
Kulkarni, Tejaswini
Newton, Chad A.
Gupta, Sachin
Samara, Katerina
Bernstein, Elana J.
PULMONARY THERAPY, 2024, 10 (03) : 331 - 346
[12] Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial
Iseki, Kunitoshi
Kabata, Daijiro
Shoji, Tetsuo
Inaba, Masaaki
Emoto, Masanori
Mori, Katsuhito
Morioka, Tomoaki
Nakatani, Shinya
Shintani, Ayumi
PLOS ONE, 2022, 17 (09):
[13] Febuxostat and renal outcomes: post-hoc analysis of a randomized trial
Kohagura, Kentaro
Kojima, Sunao
Uchiyama, Kazuaki
Yokota, Naoto
Tokutake, Eiichi
Wakasa, Yutaka
Hiramitsu, Shinya
Waki, Masako
Jinnouchi, Hideaki
Kakuda, Hirokazu
Hayashi, Takahiro
Kawai, Naoki
Sugawara, Masahiro
Mori, Hisao
Tsujita, Kenichi
Matsui, Kunihiko
Hisatome, Ichiro
Ohya, Yusuke
Kimura, Kazuo
Saito, Yoshihiko
Ogawa, Hisao
HYPERTENSION RESEARCH, 2023, 46 (06) : 1417 - 1422
[14] Febuxostat and renal outcomes: post-hoc analysis of a randomized trial
Kentaro Kohagura
Sunao Kojima
Kazuaki Uchiyama
Naoto Yokota
Eiichi Tokutake
Yutaka Wakasa
Shinya Hiramitsu
Masako Waki
Hideaki Jinnouchi
Hirokazu Kakuda
Takahiro Hayashi
Naoki Kawai
Masahiro Sugawara
Hisao Mori
Kenichi Tsujita
Kunihiko Matsui
Ichiro Hisatome
Yusuke Ohya
Kazuo Kimura
Yoshihiko Saito
Hisao Ogawa
Hypertension Research, 2023, 46 : 1417 - 1422
[15] Pirfenidone Delays the Prescription of Concomitant Drugs in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Japanese Phase III Clinical Trial
Suzuki, A.
Sakaguchi, H.
Ebina, M.
Azuma, A.
Ogura, T.
Taguchi, Y.
Suga, M.
Takahashi, H.
Sugiyama, Y.
Kudoh, S.
Nukiwa, T.
Miyazawa, S.
Sakamoto, K.
Kondoh, Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[16] A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
Abe, Koji
Itoyarna, Yasuto
Tsuji, Shoji
Sobue, Gen
Aoki, Masashi
Doyu, Manabu
Hamada, Chikuma
Togo, Masanori
Yoneoka, Takatomo
Tanaka, Masahiko
Akimotot, Makoto
Nakamura, Kazue
Takahashi, Fumihiro
Kondo, Kazuoki
Yoshino, Hiide
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 : 11 - 19
[17] Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
Huizinga, Thomas
Toes, Rene
Weinblatt, Michael
Schiff, Michael
Fleischmann, Roy
Elbez, Yedid
Connolly, Sean
Maldonado, Michael
Gao, Sheng
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[18] Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes
Wong, Nathan C.
Alvim, Ricardo G.
Sjoberg, Daniel D.
Shingarev, Roman
Power, Nicholas E.
Spaliviero, Massimiliano
Murray, Katie S.
Benfante, Nicole E.
Hakimi, A. Ari
Russo, Paul
Coleman, Jonathan A.
EUROPEAN UROLOGY FOCUS, 2019, 5 (06): : 977 - 979
[19] Understanding clinical trial outcomes: design, analysis, and interpretation
Jacobe, Heidi T.
Leitenberger, Justin J.
Bergstresser, Paul R.
DERMATOLOGIC THERAPY, 2007, 20 (02) : 77 - 85
[20] EARLY MUCOSAL HEALING AT WEEK 10 WITH OZANIMOD PREDICTS CLINICAL OUTCOMES AT WEEK 52: POST HOC ANALYSIS OF THE PHASE 3 TRUE NORTH CLINICAL TRIAL
Longman, Randy
Axelrad, Jordan E.
Ahmad, Harris
Pondel, Marc
Ather, Shabana
Elegbe, Ayanbola
Sminsky, Charles
Reinisch, Walter
GASTROENTEROLOGY, 2022, 162 (07) : S972 - S972

← 1 2 3 4 5 →